Sahar Iftikhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sahar Iftikhar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Xiao
Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Amal Freigoun
School of Medicine, Medical Sciences and Nutrition University of Aberdeen Aberdeen Scotland, UK
1 shared publication - Caroline Vermeren
School of Medicine, Medical Sciences and Nutrition University of Aberdeen Aberdeen Scotland, UK
1 shared publication Christelle Q. Kanda
School of Medicine, Medical Sciences and Nutrition University of Aberdeen Aberdeen Scotland, UK
1 shared publicationElissa Burr
School of Medicine, Medical Sciences and Nutrition University of Aberdeen Aberdeen Scotland, UK
1 shared publication- Emad H. Aly
University of Aberdeen, Aberdeen, UK
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 514
KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target
Purpose: This review aims to provide an updated overview of Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations in colorectal carcinoma (CRC), focusing on their role in tumorigenesis, prognostic implications, and recent advances in targeted therapy. Major findings: KRAS mutations occur in approximately 40% of colorectal cancers and play a central role in tumour initiation and progression through constitutive activation of MAPK pathways. Clinically, KRAS mutations are well established as predictors of resistance to anti-EGFR therapy. Increasing evidence also supports their role as prognostic biomarkers, with KRAS-mutant tumours associated with increased recurrence risk and reduced survival, including in patients undergoing hepatic metastasectomy. Therapeutically, recent advances, most notably KRAS G12C inhibitors and combination strategies targeting upstream or parallel pathways, have expanded treatment options, although efficacy varies across KRAS mutation subtypes. Conclusions: KRAS mutations have important implications for the behaviour, prognosis, and management of colorectal cancer. Integrating KRAS mutational status into clinical decision-making may enable more personalised prognostication and treatment strategies. Continued research is required to broaden effective targeted therapies for the diverse spectrum of KRAS-mutant disease.
- 28 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 514
Open AccessKRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target
Purpose: This review aims to provide an updated overview of Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations in colorectal carcinoma (CRC), focusing on their role in tumorigenesis, prognostic implications, and recent advances in targeted therapy. Major findings: KRAS mutations occur in approximately 40% of colorectal cancers and play a central role in tumour initiation and progression through constitutive activation of MAPK pathways. Clinically, KRAS mutations are well established as predictors of resistance to anti-EGFR therapy. Increasing evidence also supports their role as prognostic biomarkers, with KRAS-mutant tumours associated with increased recurrence risk and reduced survival, including in patients undergoing hepatic metastasectomy. Therapeutically, recent advances, most notably KRAS G12C inhibitors and combination strategies targeting upstream or parallel pathways, have expanded treatment options, although efficacy varies across KRAS mutation subtypes. Conclusions: KRAS mutations have important implications for the behaviour, prognosis, and management of colorectal cancer. Integrating KRAS mutational status into clinical decision-making may enable more personalised prognostication and treatment strategies. Continued research is required to broaden effective targeted therapies for the diverse spectrum of KRAS-mutant disease.
- Open Access
- 3 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71673
Male Breast Cancer: Growing Insights and Continuing Challenges
Background: Breast cancer (BC) in men accounts for less than 1% of all BC diagnoses worldwide. Despite its low incidence, the number of men being diagnosed is increasing. Historically perceived as a predominantly female disease, BC in men has received comparatively limited attention. Aim: This review aims to examine how BC manifests in men and explored the impact of stigma and awareness on diagnosis and prognosis. Methods: A narrative review of current literature was undertaken, including epidemiological studies, clinical research and psychosocial analyses relating to male BC. Results: Male BC shares several pathological and molecular features with female BC, but notable differences exist in presentation, tumour biology and treatment considerations. Men are more likely to present at a later stage of disease, often due to low awareness and misconception that BC affects only women. Stigma and limited targeted education further contribute to delayed medical consultation. Discussion: Although understanding of male BC has improved, challenges remain in early detection and awareness. The gendered perception of BC may discourage men from seeking timely medical advice, leading to more advanced disease at diagnosis and potentially poorer outcomes. Conclusion: Addressing stigma, increasing public and professional education and promoting clinical research inclusive of men are essential to improving timely diagnosis and outcomes.
- 3 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71673
Open AccessMale Breast Cancer: Growing Insights and Continuing Challenges
Background: Breast cancer (BC) in men accounts for less than 1% of all BC diagnoses worldwide. Despite its low incidence, the number of men being diagnosed is increasing. Historically perceived as a predominantly female disease, BC in men has received comparatively limited attention. Aim: This review aims to examine how BC manifests in men and explored the impact of stigma and awareness on diagnosis and prognosis. Methods: A narrative review of current literature was undertaken, including epidemiological studies, clinical research and psychosocial analyses relating to male BC. Results: Male BC shares several pathological and molecular features with female BC, but notable differences exist in presentation, tumour biology and treatment considerations. Men are more likely to present at a later stage of disease, often due to low awareness and misconception that BC affects only women. Stigma and limited targeted education further contribute to delayed medical consultation. Discussion: Although understanding of male BC has improved, challenges remain in early detection and awareness. The gendered perception of BC may discourage men from seeking timely medical advice, leading to more advanced disease at diagnosis and potentially poorer outcomes. Conclusion: Addressing stigma, increasing public and professional education and promoting clinical research inclusive of men are essential to improving timely diagnosis and outcomes.